Medikamenten-induzierte pulmonale Hypertonie – eine aktuelle Übersicht

S. Günther; J. Behr; H. Knoop

doi:10.1055/s-0041-108315

Pneumologie, Inhaltsverzeichnis

Pneumologie 2016; 70(05): 320-327
DOI: 10.1055/s-0041-108315

Übersicht

Medikamenten-induzierte pulmonale Hypertonie – eine aktuelle Übersicht

Drug-induced Pulmonary Hypertension – a Current Review

S. Günther

¹Univ. Paris-Sud, Faculté de Médecine, Le Kremlin Bicêtre, Frankreich

²AP-HP, Centre National de Référence de l’Hypertension Pulmonaire Sévère, Département Hospitalo-Universitaire (DHU) Thorax Innovation, Service de Pneumologie, Hôpital de Bicêtre, Le Kremlin Bicêtre, Frankreich

³UMRS_999, INSERM und Univ. Paris-Sud, Laboratoire d’Excellence (LabEx) en Recherche sur le Médicament et l’Innovation Thérapeutique (LERMIT), Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, Frankreich

,

J. Behr

⁴Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität München und Asklepios Fachkliniken München Gauting

⁵Comprehensive Pneumology Center Munich (CPC-M), Mitglied des Deutschen Zentrums für Lungenforschung

,

H. Knoop

⁶Medizinische Klinik III – Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH, Universitätsklinikum der Ruhr-Universität Bochum (UK RUB)

⁷Gemeinschaftspraxis Dr. med. Umut Knoop/Dr. med. Heiko Knoop, Gelsenkirchen

› Institutsangaben

Abstract

Zusammenfassung

Hintergrund: Die pulmonale Hypertonie (PH) wird nach der gegenwärtig gültigen Klassifikation in fünf Gruppen unterteilt. Zur Gruppe 1 zählt die Medikamenten-assoziierte pulmonal-arterielle Hypertonie (PAH) als eigenständige Form. Die vorliegende Arbeit gibt einen aktuellen Kenntnisstand über Medikamente, die mit der Entstehung einer PAH oder einer pulmonal veno-okklusiven Erkrankung (PVOD), einer Untergruppe der PAH, in Verbindung gebracht werden.

Methode: Es erfolgte eine selektive Literaturrecherche im Zeitraum von 1960 bis 2015 in Pubmed. Die verwendeten Suchbegriffe waren pulmonary hypertension, pulmonary arterial hypertension, pulmonary veno-occlusive disease, drug induced pulmonary hypertension und chemotherapy induced PVOD. Hauptsächlich deutsche, englische und französische Publikationen zu diesem Thema wurden berücksichtigt.

Ergebnisse: Ein Zusammenhang zwischen der Einnahme von Medikamenten und der Entstehung einer PH wurde für verschiedene Medikamente oder Substanzklassen, vor allem Appetitzügler und Interferone, aber auch für einzelne Chemotherapeutika beschrieben.

Schlussfolgerung: Viele Publikationen bezüglich der Medikamenten-induzierten PH beziehen sich auf Einzelfallberichte oder kleine Patientenkohorten. Die Medikamenten-induzierte PH ist in den vergangenen Jahren zunehmend in den Mittelpunkt gerückt und bedarf weiterer Aufklärung. Eine enge Zusammenarbeit zwischen niedergelassenen Medizinern, PH-Kompetenzzentren und Zulassungsbehörden ist daher umso bedeutsamer, um weitere potenzielle Präparate, die im Zusammenhang mit einer Arzneimittel-induzierten pulmonalen Hypertonie stehen könnten, frühzeitig zu identifizieren. Für den klinischen Alltag ist vor dem Hintergrund dieser Erkenntnisse eine gezielte Medikamentenanamnese obligat.

Abstract

Background: The current classification of pulmonary Hypertension (PH) consists of five clinical groups, and drug-induced pulmonary arterial hypertension (PAH) is classified under Group 1 as a distinct entity. Our present work encompasses the available data concerning the association between the intake of a wide range of drugs and development of PAH.

Methods: A selective literature search was performed in Pubmed to include published work between the years 1960 – 2015. For this search, the terms pulmonary hypertension, pulmonary arterial hypertension, pulmonary veno-occlusive disease, drug induced pulmonary hypertension and chemotherapy induced PVOD were used. Mainly German, English and French publications regarding this topic were considered.

Results: An association between drug intake and PH development was described for different medications, among them appetite-suppressant drugs, interferon alpha and beta, but also several chemotherapeutic drugs.

Conclusions: The present literature regarding drug-induced PH mainly comprises case reports and small patient cohorts. Drug-induced PH has become increasingly discussed in recent years and needs further elucidation. A close cooperation between clinicians, PH expert centers and regulatory agencies is mandatory to identify other potential drugs at an early stage that may be linked to PH development. For the clinician, a thorough patient interview including drug history is necessary in the evaluation of a patient with PH.

Volltext

Referenzen

Literatur
1 Simonneau G, Gatzoulis MA, Adatia I et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (Suppl. 25) D34-41
2 Hoeper MM, Bogaard HJ, Condliffe R et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (Suppl. 25) D42-50
3 Lantuéjoul S, Sheppard MN, Corrin B et al. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006; 30: 850-857
4 Holcomb BW, Loyd JE, Ely EW et al. Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000; 118: 1671-1679
5 Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162: 1964-1973
6 Perros F, Günther S, Ranchoux B et al. Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. Circulation 2015; 132: 834-847
7 Ranchoux B, Günther S, Quarck R et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol 2015; 185: 356-371
8 Galiè N, Humbert M, Vachiery J-L et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67-119
9 Mielke H, Seiler KU, Stumpf U et al. [Relation between serotonin metabolism and pulmonary hypertension in rats following administration of various anorectic drugs]. Z Kardiol 1973; 62: 1090-1098
10 Fishman AP. Aminorex to fen/phen: an epidemic foretold. Circulation 1999; 99: 156-161
11 Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa 1985; 27: 160-171
12 Gurtner HP. [Chronic pulmonary hypertension of vascular origin, plexogenic pulmonary arteriopathy and the appetite depressant aminorex: addenda to an epidemic]. Schweiz Med Wochenschr 1985; 115: 782-789contd
13 Greiser E. [Epidemiologic studies on the relation between use of appetite depressants and primary vascular pulmonary hypertension]. Internist 1973; 14: 437-442
14 Montani D, Seferian A, Savale L et al. Drug-induced pulmonary arterial hypertension: a recent outbreak. Eur Respir Rev Off J Eur Respir Soc 2013; 22: 244-250
15 Abenhaim L, Moride Y, Brenot F et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-616
16 Khan MA, Herzog CA, St Peter JJV et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998; 339: 713-718
17 Souza R, Humbert M, Sztrymf B et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008; 31: 343-348
18 Simonneau G, Fartoukh M, Sitbon O et al. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998; 114 (Suppl. 03) 195S-199S
19 Weir EK, Reeve HL, Huang JM et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996; 94: 2216-2220
20 Boutet K, Frachon I, Jobic Y et al. Fenfluramine-like cardiovascular side-effects of benfluorex. Eur Respir J 2009; 33: 684-688
21 Bondon-Guitton E, Prévôt G, Didier A et al. Pulmonary arterial hypertension and benfluorex: 5 case reports. Thérapie 2011; 66: 135-138
22 Savale L, Chaumais M-C, Cottin V et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 2012; 40: 1164-1172
23 Brenot F, Herve P, Petitpretz P et al. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70: 537-541
24 Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-588
25 Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095-3105
26 Kennedy SH, Lam RW, Cohen NL et al. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry Rev Can Psychiatr 2001; 46 (Suppl. 01) 38S-58S
27 Seferian A, Chaumais M-C, Savale L et al. Drugs induced pulmonary arterial hypertension. Presse Médicale Paris Fr 1983 2013; 42: e303-310
28 Tiefenbrunn LJ, Riemenschneider TA. Persistent pulmonary hypertension of the newborn. Am Heart J 1986; 111: 564-572
29 Kieler H, Artama M, Engeland A et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012; 344: d8012
30 Chambers CD, Hernandez-Diaz S, Van Marter LJ et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579-587
31 Andrade SE, McPhillips H, Loren D et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009; 18: 246-252
32 Huybrechts KF, Bateman BT, Palmsten K et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA 2015; 313: 2142-2151
33 Montani D, Bergot E, Günther S et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137
34 Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?. Chest 2006; 130: 1657-1663
35 Murray RJ, Smialek JE, Golle M et al. Pulmonary artery medial hypertrophy in cocaine users without foreign particle microembolization. Chest 1989; 96: 1050-1053
36 Tseng YT, Padbury JF. Expression of a pulmonary endothelial norepinephrine transporter. J Neural Transm (Vienna) 1998; 105: 1187-1191
37 Marcos E, Fadel E, Sanchez O et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 2004; 94: 1263-1270
38 Salvi SS. Alpha1-adrenergic hypothesis for pulmonary hypertension. Chest 1999; 115: 1708-1719
39 Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037
40 Hong JH, Lee S-E, Choi SY et al. Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia. Cancer Res Treat Off J Korean Cancer Assoc 2015; 47: 937-942
41 Liu B, Wang Y, Mi Y et al. [Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review]. Zhonghua xueyexue zazhi 2014; 35: 581-586
42 Barst RJ, Abenhaim L. Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure. Heart Br Card Soc 2004; 90: e42
43 Anderson P, Höglund M, Rödjer S. Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies. Am J Hematol 2003; 73: 54-58
44 Fok A, Williams T, McLean CA et al. Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients. Mult Scler Houndmills Basingstoke Engl 2015;
45 Piroddi IMG, Barlascini C, Nicolini A. Severe Respiratory Failure Due to Interferon Beta-Related Pulmonary Hypertension. Am J Ther 2015;
46 Gibbons E, Promislow S, Davies RA et al. Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Can Respir J J Can Thorac Soc 2015; 22: 263-265
47 Savale L, Sattler C, Günther S et al. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J 2014; 44: 1627-1634
48 Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
49 Sarrazin C, Berg T, Buggisch P et al. [S3 guideline hepatitis C addendum]. Z Gastroenterol 2015; 53: 320-334
50 Brillanti S, Garson J, Foli M et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-817
51 Kowdley KV, Lawitz E, Poordad F et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370: 222-232
52 Fruehauf S, Steiger S, Topaly J et al. Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia. Ann Hematol 2001; 80: 308-310
53 Hanaoka M, Kubo K, Hayano T et al. Interferon-alpha elevates pulmonary blood pressure in sheep--the role of thromboxane cascade. Eur J Pharmacol 1999; 370: 145-151
54 George PM, Oliver E, Dorfmuller P et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res 2014; 114: 677-688